Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer

IMPORTANCE: Combining conventional chemotherapy with targeted therapy has been proposed to improve the pathologic complete response (pCR) rate in patients with inflammatory breast cancer (IBC). Epidermal growth factor receptor (EGFR) expression is an independent predictor of low overall survival in...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JAMA Oncol
Κύριοι συγγραφείς: Matsuda, Naoko, Wang, Xiaoping, Lim, Bora, Krishnamurthy, Savitri, Alvarez, Ricardo H., Willey, Jie S., Parker, Charla A., Song, Juhee, Shen, Yu, Hu, Jianhua, Wu, Wenhui, Li, Nan, Babiera, Gildy V., Murray, James L., Arun, Banu K., Brewster, Abenaa M., Reuben, James M., Stauder, Michael C., Barnett, Chad M., Woodward, Wendy A., Le-Petross, H. T. Carisa, Lucci, Anthony, DeSnyder, Sarah M., Tripathy, Debu, Valero, Vicente, Ueno, Naoto T.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Medical Association 2018
Θέματα:
Original Investigation
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143003/
https://ncbi.nlm.nih.gov/pubmed/29879283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.1436
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια